Market Place
Sourcing Support
Blueprint Medicines Raises AYVAKIT® Revenue Guidance for 2024
30 Oct 2024 //
PR NEWSWIRE
Blueprint Medicines To Report Q3 2024 Results On October 30
16 Oct 2024 //
PR NEWSWIRE
Blueprint Medicines to Present at Upcoming Investor Conferences
10 Sep 2024 //
PR NEWSWIRE
Blueprint Launches `Colors Of SM` Awareness Program
01 Aug 2024 //
FIERCE PHARMA
Blueprint Medicines Reports Q2 2024, Raises AYVAKIT® Guidance
01 Aug 2024 //
PR NEWSWIRE
Blueprint AYVAKIT Data At EAACI EHA Highlight Sustained Benefit
30 May 2024 //
PR NEWSWIRE
Blueprint Cdk2 Cdk4/6 Combo Positive: First Breast Cancer Data Asco24
23 May 2024 //
PR NEWSWIRE
Blueprint Medicines Inducement Grants Under Nasdaq Rule
06 May 2024 //
PR NEWSWIRE
Blueprint Reports Strong Q1 2024, Raises AYVAKIT® Revenue Guidance
02 May 2024 //
PR NEWSWIRE
Blueprint Medicines Q1 2024 Results On May 2
18 Apr 2024 //
PR NEWSWIRE
Blueprint Medicines Webcast On Mast Cell Therapy Opportunities
11 Apr 2024 //
PR NEWSWIRE
Blueprint Med Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Apr 2024 //
PR NEWSWIRE
Blueprint Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Mar 2024 //
PR NEWSWIRE
Blueprint Medicines Highlights AYVAKIT Long-Term Efficacy and Safety Data
23 Feb 2024 //
PR NEWSWIRE
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
15 Feb 2024 //
PR NEWSWIRE
Blueprint boosts Ayvakit peak sales estimate to $2B
15 Feb 2024 //
FIERCE PHARMA
Blueprint Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Feb 2024 //
PRESS RELEASE
Blueprint Medicines to Report Fourth Quarter & Full Year 2023 Financial Results
01 Feb 2024 //
PRESS RELEASE
Blueprint drops lung cancer programs after seeing early data
10 Jan 2024 //
FIERCE BIOTECH
VantAI Secures Support from Blueprint to Chart Frontiers in Drug Discovery
09 Jan 2024 //
BUSINESSWIRE
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities
08 Jan 2024 //
PRESS RELEASE
Blueprint Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Jan 2024 //
PRESS RELEASE
EC approves treatment for rare haematological disorder
13 Dec 2023 //
EUROPEAN PHARMACEUTICAL REVIEW
Blueprint`s Leadership in Driving Continued Innovation in Systemic Mastocytosis
09 Dec 2023 //
PRESS RELEASE
Blueprint Medicines Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
04 Dec 2023 //
PRESS RELEASE
Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit
28 Nov 2023 //
PRESS RELEASE
Blueprint Medicines` AYVAKYT® (avapritinib) Receives Positive CHMP Opinion
10 Nov 2023 //
PR NEWSWIRE
Blueprint Medicines Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
03 Nov 2023 //
PRESS RELEASE
Why Blueprint Medicines Stock Soared Today
26 Oct 2023 //
FOOL
Blueprint Medicines Reports Third Quarter 2023 Results
26 Oct 2023 //
PR NEWSWIRE
Blueprint Medicines to Report Third Quarter 2023 Financial Results
12 Oct 2023 //
PRESS RELEASE
Blueprint Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Oct 2023 //
PRESS RELEASE
Blueprint Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Sep 2023 //
PR NEWSWIRE
Genentech, Blueprint tout full approval for Gavreto in rare type of lung cancer
10 Aug 2023 //
ENDPTS
QIAGEN receives FDA approval for companion diagnostic to Blueprint™ AYVAKIT
07 Aug 2023 //
GLOBENEWSWIRE
Blueprint Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Aug 2023 //
PR NEWSWIRE
Lilly pressures Blueprint further with positive NSCLC readout
04 Aug 2023 //
FIERCE PHARMA
Blueprint Medicines Reports Second Quarter 2023 Results
02 Aug 2023 //
PR NEWSWIRE
Blueprint Medicines to Report Second Quarter 2023 Financial Results
19 Jul 2023 //
PRESS RELEASE
Blueprint Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Jul 2023 //
PRESS RELEASE
Roche pulls a Gavreto approval before Blueprint severance, citing unfeasible trial
05 Jul 2023 //
FIERCE PHARMA
Alexis Borisy loses majority investor support at Blueprint
28 Jun 2023 //
FIERCE PHARMA
Blueprint investors are sitting on a loss of 24% if they invested five years ago
09 Jun 2023 //
FINANCE YAHOO
Blueprint Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Jun 2023 //
PRESS RELEASE
Blueprint Medicines Highlights Progress Across Precision Oncology Pipeline
03 Jun 2023 //
PR NEWSWIRE
NEJM Evidence Publishes Results from Registrational PIONEER Trial
23 May 2023 //
PRESS RELEASE
FDA Approves AYVAKIT as Only Treatment for Indolent Systemic Mastocytosis
23 May 2023 //
PR NEWSWIRE
Blueprint Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 May 2023 //
PRESS RELEASE
Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy
26 Apr 2023 //
PR NEWSWIRE
Blueprint Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Apr 2023 //
PRESS RELEASE
Blueprint`s solid tumor med permitted to resume trial
29 Mar 2023 //
FIERCE BIOTECH
Blueprint Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Mar 2023 //
PR NEWSWIRE
Ahead of FDA decision, Blueprint puts out full data for expanded Ayvakit label
27 Feb 2023 //
ENDPTS
Blueprint Medicines Presents Registrational Data from PIONEER Trial of AYVAKIT
26 Feb 2023 //
PR NEWSWIRE
After splashing $1B, Roche returns Gavreto to Blueprint
24 Feb 2023 //
FIERCE PHARMA
Blueprint lays out $1.5B expansion plan for Ayvakit
18 Feb 2023 //
FIERCE PHARMA
Blueprint Medicines Reports Fourth Quarter and Full Year 2022 Results
16 Feb 2023 //
PR NEWSWIRE
Blueprint Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222
11 Feb 2023 //
PRESS RELEASE
Blueprint Medicines to Report Q4 and Full Year 2022 Financial Results
09 Feb 2023 //
PR NEWSWIRE
Blueprint Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Feb 2023 //
PRESS RELEASE
